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Immunoglobulin 4 (IgG4) is one of four human IgG subclasses and has several unique functional characteristics.
It exhibits low affinity for complement and for most Fc receptors. It furthermore has generally high affinity for its
antigen, with binding occurring in a monovalent fashion, as IgG4 can exchange Fab-arms with other IgG4 molecules.
Because of these characteristics, IgG4 is believed to block its targets and prevent inflammation, which, depending on
the setting, can have a protective or pathogenic effect. One example of IgG4 pathogenicity is muscle-specific kinase
(MuSK) myasthenia gravis (MG), in which patients develop IgG4 MuSK autoantibodies, resulting in muscle weakness.
As a consequence of the distinct IgG4 characteristics, the pathomechanism of MuSK MG is very different from IgG1-
and IgG3-mediated autoimmune diseases, such as acetylcholine receptor MG. In recent years, new autoantibodies in
a spectrum of autoimmune diseases have been discovered. Interestingly, some were found to be predominantly IgG4.
These IgG4-mediated autoimmune diseases share many pathomechanistic aspects with MuSK MG, suggesting that
IgG4-mediated autoimmunity forms a separate niche among the antibody-mediated disorders. In this review, we
summarize the group of IgG4-mediated autoimmune diseases, discuss the role of IgG4 in MuSK MG, and highlight
interesting future research questions for IgG4-mediated autoimmunity.
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Introduction to IgG4
Antibody responses are an effective strategy of the
immune system to protect against pathogens, but,
when they go awry, they can also cause disease.
Human antibody responses can consist of imma-
ture, low-affinity immunoglobulin (Ig) IgM and IgD
responses or more mature IgE and IgG responses.
IgG is further subdivided into subclasses on the
basis of their morphological and functional char-
acteristics. Structural determinants in the constant,
crystallizable fragment (Fc) of the antibody dic-
tate whether an immunoglobulin G (IgG) molecule
is able to activate complement, bind and activate
or inhibit Fc receptors and immune cell–mediated
cytotoxicity, or interact with other IgGs.1 On the
basis of these characteristics and the type of antigen,
human IgG was classified into four subclasses. IgG4
is the least prevalent IgG in healthy adults and makes
up approximately 5% of the total IgG pool. Despite
an approximately 90% amino acid sequence homol-
ogy with other IgG subclasses, IgG4 is unique, as it
is functionally monovalent and causes little to no
inflammation.2 IgGs normally appear as homod-
imers, but two residues (serine 228 and arginine
409) in IgG4 Fc facilitate continuous exchange of
monomers, a process termed Fab-arm exchange.3,4
This results in bispecific antibodies and functionally
monovalent binding. In other words, each Fab-arm
of an IgG4 molecule will bind a different antigen,
which disables its crosslinking capacity and inhibits
immune complex formation. The lack of immune
complex formation together with reduced binding
affinity for complement factor C1q renders IgG4 a
poor complement activator.5 Furthermore, interac-
tion with Fc receptors on immune cells is dependent
on the individual receptor and specific residues in
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the CH2 region of the Fc of an IgG molecule. For
IgG4, these Fc determinants result in preferred bind-
ing to inhibitory Fc receptors.6 Lastly, when solid-
phase immobilization is used, IgG4 Fc can bind to
other Fc receptors from all human IgG subclasses.7
Together, these distinct functional characteristics led
IgG4 to be deemed as an anti-inflammatory anti-
body. For a comprehensive review on IgG4 mor-
phology and function and the regulation of IgG4
responses, see Lighaam et al.1
For each of the unique features of IgG4, the
(patho-)physiological relevance is largely unclear.
Depending on the setting, an IgG4 response can be
protective or pathogenic. For example, IgG4 is often
considered a protective blocking antibody, as it can
inhibit or prevent inflammation by competing for
antigen binding with inflammatory IgG subclasses
or IgE. Alternatively, IgG4 can cause severe disease in
a subset of autoimmune diseases, which is discussed
below.
IgG4-mediated autoimmune diseases
The majority of known antibody-mediated
autoimmune diseases are caused by IgG1 and IgG3
autoantibodies. However, in the 1980s, pemphigus,
a skin-blistering disease, was recognized as the
first autoimmune disease that is hallmarked by
IgG4 autoantibody predominance.8 In recent years,
autoimmunity research has focused, for both
diagnostic and treatment purposes, on identifying
new antigens in a variety of autoimmune diseases.
Identification of these new antigens created an
opportunity to characterize the predominant
antibody subclass and disease mechanisms. To our
knowledge, IgG4 plays a prominent role in the
pathogenesis of at least 13 autoimmune diseases.
For an extensive review on these diseases, see
Huijbers et al.9 The idea that IgG4-mediated
autoimmune diseases constitute a separate niche
among the antibody-mediated autoimmune dis-
eases is based on several observations (Table 1).
The differences between IgG1-, IgG3-, and IgG4-
mediated autoimmune diseases mostly relate to
the functional characteristics of the different IgG
subclasses. Where IgG1 and IgG3 autoantibodies
cause disease by inducing complement-dependent
tissue damage, immune cell–mediated cytotoxicity,
and crosslinking and internalization of the antigen,
those IgG4 autoantibodies for which the disease
mechanism is largely resolved simply block the
function of its target antigen. It is furthermore
interesting that IgG4-mediated autoimmune
diseases are rarely associated with tumors.10
Since our first review on the group of IgG4-
mediated autoimmune diseases, one disease entity
can be added: neurofascin140/186 antibodies in
patients with chronic inflammatory demyelinat-
ing polyneuropathy (CIDP).9,11 For several of the
other IgG4-mediated autoimmune diseases, more
evidence has been presented for a pathophysiolog-
ical relationship between the IgG4 autoantibodies
and disease. An overview of the main characteristics
of the IgG4-mediated autoimmune diseases is given
in Table 2. For five out of the 13 listed diseases,
passive transfer of human total IgG or IgG4 into
experimental animals has been shown to induce the
symptoms of the respective disease. For the eight
remaining diseases, IgG4-mediated autoimmunity
is suggested by the observation that serum-derived,
antigen-specific autoantibodies are predominantly
of the IgG4 subclass and that their titers corre-
late with disease severity. In vitro assays have fur-
thermore elucidated the pathomechanism by which
these (IgG4) autoantibodies cause disease in 12 of
the 13 listed diseases.
Interestingly, there is a second group of diseases
hallmarked by IgG4 autoantibody predominance,
but in this group the role of IgG4 in the pathophys-
iology is unclear. For example, IgG4 autoantibod-
ies dominate the response in bullous pemphigoid
patients with BP180 and BP230 autoantibodies in a
subset of patients with Goodpasture disease with
collagen IV autoantibodies and in patients with
encephalitis and dipeptidyl-peptidase–like protein 6
autoantibodies (DPPX).12–15 However, IgG1-related
effector functions dictate the pathophysiology in
these diseases. This is likely due to the co-occurrence
of IgG1 autoantibodies and calls into question the
role of IgG4 autoantibodies in the pathomecha-
nism of these diseases. Lastly, anti-cyclic citrul-
linated protein (ACPA) antibodies are associated
with rheumatoid arthritis and are often of the IgG1
and IgG4 subclasses.16 The role of ACPA antibod-
ies in rheumatoid arthritis pathophysiology remains
enigmatic. Since it is not clear whether diseases in
this group are truly members of the IgG4-mediated
autoimmune diseases niche, they have been sum-
marized separately (Table 3). Passive transfer studies
with purified IgG4 from these patients might help
to clarify this issue.
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Table 1. The differences between IgG1-, IgG3-, and IgG4-mediated autoimmune disease
IgG1 and IgG3 IgG4
Antigens are receptors, ion channels, or multisubunit proteins Antigens are typically not receptors, ion channels, or
multisubunit proteins
Pathomechanism requires complement and immune
cell–mediated cytotoxicity and inflammation
Pathomechanism is blocking of essential protein–protein
interactions
Structural damage to target tissue No structural damage to target tissue
Crosslinking and internalization of the antigen Monovalent antigen binding; no crosslinking
Sometimes associated with paraneoplastic events No clear tumor association
Result from TH1-related cytokine expression Result from TH2-related cytokine expression
The first IgG4-mediated autoimmune diseases to
be described were mainly neurological disorders.9
However, it is clear that IgG4-mediated autoimmu-
nity can also affect other organ systems. In fact, five
out of 13 IgG4 diseases do not affect the nervous
system. It can be expected that this niche will grow
in the coming years as more antigenic targets are
discovered.
The identification of a new niche warrants further
investigation on the commonalities and differences
between these diseases, as it might shed light on the
cause and shared potential therapeutic opportuni-
ties. A summary of commonalities and differences
between the IgG4-mediated autoimmune diseases
is given in Table 4. Many of the antigens that are
involved in IgG1- and IgG3-mediated autoim-
mune diseases are multisubunit receptors or ion
channels,10 as exemplified by acetylcholine receptor
(AChR) myasthenia gravis (MG). Notably, the IgG4
autoantibodies described thus far do not seem to
target multisubunit receptors or ion channels, but
rather bind proteins associated with them.9 These
antigens are often involved in stabilizing the ion
channels or receptors or are themselves important
for maintaining cell–cell interactions. For example,
muscle-specific kinase (MuSK) is essential in
establishing and maintaining the neuromuscular
junction (NMJ) and induces AChR clustering,
while desmogleins maintain keratinocyte cell–cell
interactions. Thus, the antigens either function as
bridging proteins themselves or participate in a sig-
naling cascade that facilitates cell–cell interactions.
The IgG4 autoantibodies (physically) interfere
in the (signaling) function of the antigens and
hamper the bridging effects.9 Lastly, in thrombotic
thrombocytopenic purpura with ADAMTS13
IgG4 autoantibodies, the interaction between
ADAMTS13 and its substrate von Willebrand factor
is obstructed, preventing the degradation of the
substrate.17 In conclusion, the blocking nature of
IgG4 can result in pathology through obstruction
of three different protein functions (Fig. 1).
Initially, few human leukocyte antigen (HLA)
associations were reported for the IgG4-mediated
autoimmune diseases, and it was striking that three
of them showed an HLA-DQ5 association (MuSK
MG, IgLON5 non-REM and REM parasomnia, and
pemphigus vulgaris in Jewish patients).9 However,
Tables 2 and 3 show that IgG4 autoimmunity is not
restricted to HLA-DQ5. HLA association studies are
further limited for some of these diseases owing to
the small number of patients described.
Immunosuppression generally forms the first-
line treatment for all of these diseases, but not all
patients respond well to these therapies. The obser-
vation that rituximab seems particularly effective in
IgG4-mediated autoimmune diseases is therefore of
great clinical value. Rituximab is a CD20 antibody
that depletes all CD20-expressing B cells. Whether
IgG4-producing B cells are particularly sensitive to
this treatment, and why, is not known. The level
of CD20 does not seem to differ between IgG4
and IgG1 memory B cells, and rituximab lowers
all IgG subclass levels in bullous pemphigoid.18,19
Moreover, the numbers of total B cells, as well as
naive, memory, plasmablast, and transitional B cell
subsets, are normal in MuSK MG and pemphi-
gus patients.20,21 The rapid and sustained reduction
in IgG4 autoantibody titers therefore suggests that
IgG4 responses might not be dominated by long-
lived plasma cells and that IgG4 plasma cells express
CD20.22,23 It will be exciting to learn why rituximab
treatment is particularly effective in these diseases.
Several features differ among IgG4-mediated
autoimmune diseases (Tables 2–4). These include
the antigen that is recognized, the different types of
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Table 2. Overview of the characteristics and experimental evidence for the IgG4-mediated autoimmune diseases
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Table 2. Continued








































































































































protein domains that form the main immunogenic
region (MIR), the need for glycosylation of the
antigen for autoantibody binding, the type of
HLA association, and the VDJ gene usage of the
autoantibodies. Given that many of these disease
subsets have only recently been recognized, these
details are not yet comprehensively available. For
11 IgG4-mediated autoimmune diseases, the MIR
has been mapped, and for five of them the MIR is
an Ig-like domain, for three a fibronectin domain,
and for two a cadherin-like domain. This suggests
that different types of protein domains can be
involved in an IgG4 autoimmune response. With
more diseases being discovered, it will be interesting
to learn whether certain protein domains and
structures are more prone to IgG4 responses.
Epitope-mapping experiments in all these diseases
further suggest that the autoantibody repertoire is
Figure 1. A graphic representation of the three main pathological blocking effects of IgG4 autoantibodies. The diseases for which
the pathomechanism is well characterized are grouped below the associated IgG4 effects.
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Table 3. Overview of autoimmune diseases hallmarked by high levels of IgG4 autoantibodies but with poorly defined
roles for IgG4 in the disease












































































































































oligo- or polyclonal, as epitopes outside the MIR
are being recognized as well. Another important
determinant of epitope structure is glycosylation.
Therefore, for some antigens, the contribution of
glycosylation to autoantibody–antigen binding has
been studied. Thus far, contactin 1 in CIDP is the
only antigen for which glycosylation was proven
to be essential for autoantibody binding.24 For the
other IgG4-mediated autoimmune diseases, it may
be possible that, while the autoimmune response
develops, epitope spreading moves the immune
response away from glycosylation-dependent epi-
topes. Given the involvement of different antigens
and MIRs, it is not surprising that VDJ usage and
HLA associations differ between these diseases,
although it is important to realize that human
monoclonal antibodies have only been isolated for
three out of the 13 listed diseases. Lastly, for some
IgG1- and IgG3-mediated autoimmune diseases,
paraneoplastic events are associated with the onset
of disease. Such associations have thus far only
been observed in a limited number of patients with
IgG4 autoimmunity, which suggests that it is less
relevant for IgG4.10,25,26
Evidence for IgG4 involvement
in MuSK MG
Witebsky’s postulates require confirmation of
autoimmunity on several levels.27 The role of MuSK
autoantibodies in MG is supported by the transpla-
cental transfer of disease, by active immunization of
mice and rabbits with the MuSK antigen inducing
MG, and by passive transfer of both total IgG and
purified IgG4 from MuSK MG patients into mice
and rabbits.28–35 The role of IgG4 in MuSK MG was
first suggested by the observations that the majority
of the MuSK autoantibodies are of the IgG4
subclass and that IgG4 titers correlate with disease
severity.36–38 Direct evidence for the role of IgG4 in
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Table 4. An overview of the commonalities and differences between the several specific IgG4-mediated autoimmune
diseases
Commonalities
 Predominating IgG4 autoantibodies
 The antigens (so far) do not include essential ion channels or multisubunit receptors
 The antigens are part of important protein–protein interactions that maintain cell–cell contact, stabilize ion channels, or
mediate proteolysis
 The antigens are highly N-glycosylated
 The pathogenic mechanism is blocking of protein–protein interaction and function
 Strong HLA class II associations
 Good response to rituximab treatment
Differences
 The antigens recognized
 Main immunogenic regions reside in different types of protein domains
 Some require proper antigen glycosylation for autoantibody–antigen binding
 Type of HLA class II genes associated
 Type of VDJ gene usage
MuSK MG comes from passive transfer experiments
with affinity-purified polyclonal IgG4 antibodies
from MuSK MG patients.30 A pathogenic potency
of monoclonal IgG4 antibodies derived from
patients would provide another level of evidence,
but such monoclonal antibodies have only recently
been isolated and have not been functionally
characterized.39 Low levels of non-IgG4 MuSK
antibodies can sometimes also be detected. Whether
they play a role in the pathophysiology of the dis-
ease is currently unclear, as purified MuSK IgG1–3
antibodies can inhibit AChR clustering in myotube
cultures but do not inhibit the LRP4–MuSK
interaction (see below).40,41 Moreover, passively
transferred purified IgG1–3 patient antibodies did
not bind the NMJ and did not cause MG in mice.30
In the in vitro studies, the dosing of MuSK-specific
antibodies was equal for IgG1–3 and IgG4, whereas
the in vivo experiments did not correct for MuSK-
specific antibody dosing.30,41 This might explain
these apparent discrepancies. The IgG1–3 MuSK
antibody titers in the majority of patients are low or
even undetectable in our experience. Furthermore,
it cannot be excluded that epitope specificity
might differ between MuSK antibodies of different
subclasses, and this may affect their pathogenicity.
Lastly, due to Fab-arm exchange, IgG4 is function-
ally monovalent. For polyclonal patient antibodies,
it was shown that these patients carry the genetic
variants that enable Fab-arm exchange, and they
do so in vitro and in vivo.42 Whether the valency
of anti-MuSK antibodies is relevant for their
pathogenicity is not known. IgG4, likely owing to
its monovalency, was shown to block the MuSK–
LRP4 interaction, thereby inhibiting the trophic
signaling cascade leading to AChR clustering. An
important step in this cascade is dimerization and
internalization of MuSK, which activates its intra-
cellular kinase domain and transmits the clustering
signal.43 It is conceivable that bivalent IgG1–IgG3
antibodies to MuSK could induce dimerization and
internalization of MuSK, which would therefore
strengthen the ongoing neuromuscular junction
maintenance pathway and would be unlikely to
result in myasthenia. The internalization might also
prevent activation of complement or immune cell–
mediated cytotoxicity. This hypothesis is consistent
with observations that MuSK can be internalized
when total IgG from patients is used in myotube
cultures and can activate AChR clustering in some
cases.41,44 Alternatively, the IgG1–3 antibodies
might also inhibit MuSK function or activate com-
plement. Lastly, the MuSK–ColQ interaction can
be blocked by patient IgG.45 Whether the subclass
of the autoantibodies is relevant for this effect is
unknown. Patient-derived monoclonal antibodies
might be important tools to address these mech-
anistic questions. In addition, it is important to
emphasize that a combination of the aforemen-
tioned effects can occur in individual patients, as
antibody repertoires likely vary. For MuSK MG, we
have not yet encountered patients with high levels
of MuSK-specific IgG1. This suggests that either
the titers of IgG1–3 autoantibodies do not reach
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Figure 2. An overview of the effect of IgG4 in different IgG4-associated diseases and potential therapeutic strategies.
pathogenic levels or that high IgG1–3 autoantibody
levels are less pathogenic in MuSK MG.
For the different forms of pemphigus, the role of
autoantibody valency has been investigated exten-
sively. In pemphigus vulgaris, active disease is asso-
ciated with IgG4 autoantibodies, the switch from
IgG1 to IgG4 autoantibodies is essential in develop-
ing symptoms in an endemic form of pemphigus,
and passive transfer of IgG4 from patients induces
the disease in mice.46–48 In contrast, some pem-
phigus foliaceus patients only have IgG1 autoan-
tibodies, which can cause acantholysis in mice.49
Epitope specificity and autoantibody pathogenic-
ity differ between autoantibodies of the IgG1 and
IgG4 subclasses.50 These observations suggest that,
in pemphigus, antibody isotype is not a major deter-
minant for the pathogenic effects and that epi-
tope specificities and autoantibody titers are more
important.51,52
Other diseases associated with IgG4
IgG4 plays a key role in a variety of other
diseases. These can be distinguished as diseases
where the blocking effect of IgG4 is beneficial
and diseases in which the IgG4 blocking effect is
pathogenic. The pathogenic effect of IgG4 is seen in
the previously discussed autoimmune diseases; in
melanoma, where IgG4 inhibits endogenous anti-
tumor responses, resulting in worse disease pro-
gression and metastasis; in treatment settings with
antibiologicals, where IgG4 blocks the function of
the biological and renders treatment ineffective; and
in a range of IgG4-related diseases where plasma
cell infiltrates cause tissue damage.9,53–56 Like in
IgG4-mediated autoimmunity, these IgG4-related
diseases form a heterologous group of autoimmune
disorders affecting a broad range of organ systems.
The symptoms relate to the organ system affected.
However, in contrast to IgG4-mediated autoimmu-
nity, increased levels of IgG4 are often found in
IgG4-related disease patients, but the exact role of
this IgG4 and whether it recognizes a specific anti-
genic target is unknown. For more specific informa-
tion on the pathology of IgG4-related disease, the
reader is referred to recent reviews.57,58 In each of
the abovementioned settings except for the IgG4-
related diseases, IgG4 antigen–specific titers corre-
late with disease severity, and a reduction in these
titers correlates with improved health.
Interestingly, IgG4 can also have protective
effects. This is seen in infections with filarial par-
asites and helminths, where IgG4 dampens ongoing
inflammation, and in situations where prolonged
inflammation or allergic responses cause serious
disease.1,59 Seminal work by Aalberse and colleagues
revealed that tolerance is induced in beekeepers that,
after prolonged immunization, have undergone a
class switch to IgG4. The IgG4 competes for binding
with IgE and IgG1 to the allergen. In addition, the
increase in IgG4 titer is an order of magnitude higher
than IgE and IgG1, which further contributes to its
competitive ability. Owing to its inability to activate
neutrophils and complement, IgG4 inhibits ongoing
inflammation, resulting in tolerance and reduced
allergic symptoms. In these settings, the increase
of antigen-specific IgG4 correlates with improved
health. Figure 2 gives an overview of the effect of
IgG4 in different IgG4-associated diseases.
Thus, depending on the setting, IgG4 can have
beneficial or detrimental effects. It is tempting to
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Table 5. An overview of the accepted knowledge and unresolved questions about MuSK MG pathophysiology and
the involvement of IgG4
Accepted knowledge
 Polyclonal patient IgG4 induces MG-like features in vitro and in vivo
 Polyclonal patient IgG1–3 sometimes induce MG-like features in vitro
 MuSK antibodies cause MG by inhibiting LRP4–MuSK signaling, resulting in AChR declustering
 MuSK antibodies in some cases induce MuSK internalization and MuSK–ColQ interaction inhibition
 Polyclonal IgG4 MuSK patient antibodies exchange Fab-arms
 The N-terminal Ig-like domain 1 is the main immunogenic region, and epitopes outside this domain exist
Unresolved questions
 Do IgG4 and IgG1 MuSK autoantibodies recognize similar epitopes?
 Can IgG1–3 MuSK autoantibodies cause MG in vivo?
 Is the valency of the autoantibodies relevant to their pathogenicity?
 Do MuSK MG patients have dysgammaglobulinemia?
 Do nonpathogenic MuSK antibodies exist?
 Are antibodies binding different epitopes on MuSK equally pathogenic?
 Do MuSK-specific IgE, IgA, and IgM exist? What is their role?
 What causes the (IgG4) MuSK autoimmune response?
 Do IgG4-mediated autoimmune diseases share a similar etiology?
 Why is rituximab such an effective therapy in MuSK MG? Why do some patients remain in stable remission while other relapse?
speculate that specific modulation of IgG4 produc-
tion could be a promising therapeutic strategy for
all of the abovementioned IgG4-associated diseases.
It is possible that these treatments would be bet-
ter than general immunosuppression, as they might
not affect other useful immune responses. Further-
more, low levels of IgG4 are generally well toler-
ated and are therefore expected to result in fewer
side effects. Given the clinical relevance, a range
of studies have investigated the regulation of IgG4
responses. Although many aspects of the induction,
maintenance, and inhibition of IgG4 responses are
still unknown, several factors have been described
to contribute to IgG4 production: (1) prolonged
exposure to an allergen;60 (2) TH2-related cytokines
interleukin (IL)-4 and IL-13 inducing a class switch
to IgG4 and IL-21 and IL-4 stimulating IgG4 pro-
duction by plasma cells;61–63 (3) IL-10 derived from
regulatory T and B cells;64–66 and (4) growth hor-
mone and growth factor.67
How (and if) these factors contribute specifically
to the onset and progression of IgG4-mediated
autoimmune diseases is thus far not known. A
small number of studies have investigated whether
these factors are dysregulated in MuSK MG. These
studies are all hampered by the limited number of
patients included and the heterogeneous treatment
regimens they received. Plasma levels of TH1-, TH2-,
and TH17-related cytokines do not differ between
MuSK MG patients and healthy individuals.68 In
vitro production of IL-4, IL-6, IL-13, and TNF-
was normal in CD40+ and nonspecific B cell
receptor–stimulated MuSK MG immune cells.68,69
Transcriptomic analysis and MuSK-specific stim-
ulation did not show altered cytokine expression
compared with controls. Interestingly, interferon
 , IL-10, IL-17A, and IL-21 production were
increased in these cultures.68 Other studies have
also suggested that B cell–activating factor, a factor
that is secreted by dendritic cells and myeloid cells
to promote B cell survival, is increased in MuSK
MG patients.20,70 Furthermore, regulatory B10 cells
are reduced in MuSK MG. Each of these factors
could contribute to the breakdown of tolerance
in MuSK MG and suggest a role for TH1 and
TH17 immune regulation. The latter is particularly
striking, as IgG4 production is usually related to a
TH2 response. The increased production of IL-10 in
immune cell cultures matches its described role as
a potent IgG4 stimulator. Higher-powered studies
that also separate on the basis of treatment regimen
could shed more light on the immune status of
MuSK MG patients during the disease.
Conclusions
IgG4 is an enigmatic antibody with unique charac-
teristics that is associated with a range of (autoim-
mune) diseases. Depending on the setting, IgG4
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can have protective or pathogenic effects. There is
strong evidence that IgG4 is pathogenic in MuSK
MG and other IgG4-mediated autoimmune dis-
eases. The blocking effect of IgG4 is a pathome-
chanistic feature thus far shared by these diseases,
but mostly different from other IgG1- and IgG3-
mediated autoimmune diseases. Therefore, IgG4-
mediated autoimmune diseases constitute a newly
recognized and exciting niche among the antibody-
mediated autoimmune diseases. Many aspects of the
role and development of the IgG4 immune response
in MuSK MG and other newly identified IgG4-
mediated autoimmune diseases are still unknown
and form interesting lines of research for the future
(Table 5).
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